The Erythropoietin Stimulating Agents market is thus driven by increasing number of patients suffering from anemia, increasing applications in HIV infections and end-stage renal disorder, and risks of thrombosis, during surgeries, and pure red cell aplasia.
It has been found that over the past decade, anemia has been one of the serious diseases related to nutrition, accompanied by increased morbidity and mortality. In the major developing countries, neonatal and maternal mortalities accounted for 3 million deaths and they are considered as important contributors to global mortality. In the developed countries, deficiency of iron is one of the major causes of anemia and insufficient red blood cell production.
Other causes of anemia include parasite infections, such as ascaris, schistosomiasis, and hookworms, which can lower the hemoglobin (Hb) concentration in blood and cause heavy blood loss during menstruation.
Therefore as the number of people affected by anemia increases, the demand for erythropoietin stimulating agents also increases. Hence, the increasing anemia burden propels the demand in and growth of, this market.
Key Market Trends
Cancer Application Segment Dominates the Erythropoietin Stimulating Agents Market
The erythropoietin stimulating agent market are driven by increasing number of patients suffering from anemia that is induced due to cancer, end stage renal disease (ESRD) and HIV treatment. Anemia is observed in majority of patients undergoing cancer treatment. The severity of the disease in patients depends on the type of chemotherapy used, type and stage of neoplasia, and patient characteristics. Anemia results in fatigue, weakness, and depression, which severely reduce the quality of life of cancer patients.
In addition, anemia impairs the efficacy of cancer therapies. Clinical trials have shown that treating anemia (associated with cancer) with erythropoietin can improve the quality of life. Erythropoietin acts against two main causes of anemia in cancer patients undergoing chemotherapy, i.e., against myelosuppression and endogenous erythropoietin deficiency. Patients with cancer-related anemia are commonly prescribed erythropoietin in the form of epoetin alfa and epoetin beta. The most prescribed products include Procrit, Epogen, and NeoRecormon. With more than 75% of patients suffering from anemia due to cancer chemotherapy, the demand for erythropoietin stimulating agents increases. Hence, with the increase in cancer patients undergoing chemotherapy, the erythropoietin stimulating agents market is expected to grow during the forecast period.
North America is Expected to Hold the Largest Market Share during the Forecast Period
The market for erythropoietin stimulating agents in North America is estimated to hold the largest share on account of high occurrence of various disorders that eventually cause anemia in the region.
Erythropoietin stimulating agents have been effectively used in the treatments for various chronic diseases, like chronic kidney disease (CKD), cancer, neural, and HIV infections. For instance, the Centers for Disease Control and Prevention (CDC) estimates that more than 10% of adults in the United States suffer from CKD. The chances of having CKD increases with age, and it is common among adults aged more than 70 years. Moreover, adults with diabetes or higher blood pressure are prone to CKD. Hence with the increasing number of people at high risk for CKD the market for erythropoietin stimulating agents is expected to accelerate the market growth.
The erythropoietin stimulating agents market is moderately consolidated, and it includes global and local companies. Some of the key players in the market are Amgen, Thermo Fisher Scientific, Johnson and Johnson, F. Hoffmann La Roche, and Pfizer. Numerous pharmaceutical manufacturers are taking initiatives to develop and produce erythropoietin stimulating agents (ESAs) after the expiration of patents.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support